Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain.
The present investigation was performed to evaluate the susceptibility of seven clones isolated from the highly resistant Colombian strains, prototype of Biodeme Type III. Seven clones previously obtained, showed a phenotypic homogeneity and high similarity with the parental strain. Eight groups of 30 mice were inoculated with one of seven clones or the parental strain; 20 were treated with benznidazole (100mg/kg/day) and 10 were untreated controls. Cure evaluations were done by parasitological and serological tests and PCR. Cure rates varied from 0% (null) to 16.7%. Correlation between positivity of parasitological and serological tests with positive PCR reached 37%. The results demonstrated the high resistance of the clones, suggesting the predominance of a highly resistant principal clone in this strain. The findings apparently indicate that the possibility of cure is minimal for patients infected with this biodeme; a fact that could affect the control of Chagas' disease through treatment of chronically infected people.
Camandaroba
Edson L P
EL
Laboratorio de Doença de Chagas Experimental, Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BA, Brasil.
Reis
Eliana A G
EA
Gonçalves
Marilda S
MS
Reis
Mitermayer G
MG
Andrade
Sonia G
SG
D000818:Animals; D014355:Chagas Disease / Q000188:drug therapy* / Q000469:parasitology; D003001:Cloning, Molecular; D003105:Colombia; D004351:Drug Resistance; D051379:Mice; D009593:Nitroimidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D018512:Parasitemia / Q000188:drug therapy; D010274:Parasitology / Q000379:methods; D016133:Polymerase Chain Reaction; D014344:Trypanocidal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014349:Trypanosoma cruzi / Q000187:drug effects*
D009593:Nitroimidazoles; D014344:Trypanocidal Agents; C009999:benzonidazole